Phase I Trial Of Autologous CD19-Targeted CAR-Modified T Cells As Consolidation After Purine Analog-Based First-Line Therapy In Patients With Previously Untreated CLL
Park JH, Rivière I, Wang X et al.
Key Points:
Autologous CD19-targeted CAR-modified T cells infused as consolidative therapy to patients with high risk CLL with minimal residual disease following six cycles of chemotherapy.
Cyclophosphamide conditioning therapy used before infusing CAR+ T cells, which were given in 3 dose-escalating cohorts.
Six patients received CAR+ T cells, completing two dose cohorts of 3 x 106 and 1 x 107 CAR+ T cells/kg. No DLT observed. Cytokine release syndrome (CRS) observed in 2 patients and correlated with modified T cell persistence.
Two patients with PR following first-line chemotherapy achieved CR after T cell infusion; 2 patients maintained PR; and 2 progressed.
Implications:
- Infusion of CD19-targeted CAR+ T cells safe and demonstrated anti-tumor activity by improving CR rates in patients with high-risk CLL with minimal residual disease after 1st line chemotherapy.
View the original abstract on the ASH website.
